PHOSPHONORTONIC 20 % INJECTABLE SOLUTION

Country: Ireland

Bahasa: Inggeris

Sumber: HPRA (Health Products Regulatory Authority)

Bahan aktif:

TOLDIMFOS SODIUM TRIHYDRATE

Boleh didapati daripada:

Vetoquinol Ireland Limited

Kod ATC:

QA12CX90

INN (Nama Antarabangsa):

TOLDIMFOS SODIUM TRIHYDRATE

Dos:

20 %w/v

Borang farmaseutikal:

Solution for Injection

Jenis preskripsi:

LM-Licensed Merchant

Kumpulan terapeutik:

Bovine, Equine - Food

Kawasan terapeutik:

Toldimfos

Tanda-tanda terapeutik:

Vitamins & Minerals

Status kebenaran:

Authorised

Tarikh kebenaran:

1989-10-01

Ciri produk

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Phosphonortonic 20% Injectable Solution.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Solution for injection.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horses, cattle.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Phosphonortonic supplies organic phosphorus and is indicated in the treatment of disorders of phosphorus metabolism in
horses and cattle.
4.3 CONTRAINDICATIONS
Do not use in case of hypersensitivity to the active substance.
Do not use the product in animals suffering from renal failure.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
None.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS
None.
Each ml contains:
Active Substance
Toldimfos sodium trihydrate
20.00 % w/v
Excipients
Anhydrous Sodium Sulphite
0.20 % w/v
Phenethyl alcohol
1.00 % w/v
For a full list of excipients see 6.1
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 14/08/2015_
_CRN 7021600_
_page number: 1_
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
None known.
4.7 USE DURING PREGNANCY, LACTATION OR LAY
The product may be used in lactating animals.
No data are available on the effect of the product in pregnancy.
4.8 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION
None known.
4.9 AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE
Administration is by intravenous and intramuscular routes in several sites.
The doses recommended may be repeated every 2 or 3 days or daily according to the severity of the case: 5 to 10 injections
in chronic affections.
Horses -